Sangart Initiates Phase II Clinical Trial for Hemospan®
SAN DIEGO, CA (July 19, 2005) Sangart, Inc., a biopharmaceutical company developing oxygen transport agents, announced today the initiation of a Phase II clinical trial involving Hemospan® (MP4), a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions. This study, involving 40 patients, will be conducted at the Johns Hopkins University School of Medicine in Baltimore.
Robert M. Winslow, M.D., Chairman and Chief Executive Officer of Sangart, commented "This trial marks the initiation of Sangart's US clinical development program. It will build on the favorable safety database already established in Europe and will be the first trial of MP4 as a replacement for surgical blood loss."
Sangart's approach to the development of oxygen transport agents employs novel technology, the result of more than a decade of peer-reviewed research into the mechanism of oxygen transport by cell-free hemoglobin. Preclinical and clinical studies indicate that Hemospan® is free of harmful vasoactivity and provides targeted oxygen delivery to tissues at risk of oxygen deprivation.
Sangart is a privately held biopharmaceutical company focused on the research, development and commercialization of medical products designed for use as alternatives to blood transfusions.
Dr. Robert Winslow, a world-renowned authority in the field of oxygen transport, founded Sangart in 1998. In the two decades prior to founding Sangart, Dr. Winslow and his colleagues studied and defined mechanisms of oxygen transport by cell-free hemoglobin solutions, funded by competitive grants from the National Institutes of Health and the Department of Defense. The counterintuitive discoveries by Dr. Winslow's group on the effective action of oxygen transport agents have been patented and published in numerous scientific articles. From this experience, Sangart's lead product, Hemospan®, was designed using unique polyethylene glycol conjugation to create a hemoglobin-based product that is intended to serve as an alternative to donated blood.
The key breakthroughs in the development of Hemospan® were the understanding of the mechanisms of vasoconstriction and the development of simplified production methods that are designed to make the final product commercially viable. These breakthroughs laid the groundwork for Sangart's business concept of developing cost-effective oxygen carriers that can be used in lieu of transfused red blood cells during episodes of temporary blood loss, such as surgery or trauma.
To learn more about Sangart or Hemospan®, please visit www.sangart.com